ZVRA: Commercial Revenue, No Debt, 4x Earnings - Still Priced Like a Biotech Wager

Zevra Therapeutics announced it'll present at the Canaccord Genuity 46th Annual Growth Conference next week in Boston. That's the kind of press release investors usually skim past. But the market's treatment of Zevra is far more interesting than the conference schedule - the stock is trading at about 4 times forward earnings for a company generating over 200% year-over-year revenue growth, sitting on $237 million in cash with zero debt.

A false narrative has developed around Zevra. Wall Street still prices it like a pre-revenue biotech waiting for its first trial readout. The company is already commercial, already growing into profitability, and already cash-flow-positive on a free cash flow basis. The disconnect between how the stock trades and what the business does is the entire thesis.

1. The revenue acceleration is real - $36.2 million in Q1, up 78% from a year ago

Zevra's core product MIPLYFFA (arimoclomol) treats Niemann-Pick disease type C, a rare lysosomal storage disorder. The drug went on sale in the U.S. in 2024, and the revenue ramp has been steep. Full-year 2025 net revenue hit $106.5 million, up from $23.6 million in 2024 - a 350% jump. Q1 2026 came in at $36.2 million, with $24.6 million from MIPLYFFA alone. Prescription enrollment reached 170 patients since launch, and market access stands at 69% of covered lives.

Revenue growth YoY across the trailing twelve months sits at 201.3%. That's not a biotech that just got approved. That's a commercial product with a growing patient base and expanding insurance coverage.

2. The balance sheet is a fortress - $237 million cash, debt-free

In Q1 2026, Zevra prepaid its $63.1 million term loan in full and completed a $50 million sale of its SDX portfolio to Commave Therapeutics, receiving $40.5 million in net proceeds. The cash position at March 31 was $236.8 million. Current ratio: 489%. Debt-to-equity: 0%.

The company said available resources are sufficient to fund its strategic priorities without touching the capital markets. That removes dilution risk - one of the biggest overhangs for small-cap biotechs - and gives management optionality to pursue M&A, pipeline investment, or buybacks without pressure.

3. The EU is the next growth catalyst

Arimoclomol's Marketing Authorisation Application is under review by the European Medicines Agency. Zevra submitted its response to the EMA's 120-day list of questions during the 90-day clock-stop period in Q1, advancing the application along the standard review timeline. The drug already has Orphan Medicinal Product designation in Europe.

If approved, the EU market opens a substantial new revenue stream for a molecule that's already commercially proven in the U.S. Arimoclomol was also just included in the updated Clinical Practice Guidelines for NPC published in the Journal of Inherited Metabolic Disease, which bolsters prescribing momentum in both markets.

4. VEDS trial is the secondary pipeline optionality

The DiSCOVER Phase 3 trial testing celiprolol for Vascular Ehlers-Danlos Syndrome (a fatal connective tissue disorder) is now at 62 enrolled patients with 2 confirmed events. The trial targets 150 patients and 46 qualifying events. Zevra engaged the FDA in a Type C meeting to discuss regulatory options to accelerate development and expects a follow-up in H2 2026.

VEDS is a separate asset from MIPLYFFA with a separate addressable market. At 62 of 150 patients enrolled, the trial still has a long runway, but the optionality is priced into zero.

5. The valuation is the one-number case

At roughly 4.1x forward earnings and 4.8x trailing earnings, with consensus 2026 EPS revised up from $0.52 to $1.01, the stock trades at a deep discount to its own growth rate. Revenue grew 201% year over year; the forward PE is about 4x. Even if you assume growth slows meaningfully in 2027 and beyond, the multiple doesn't reflect a company that's 200% up on revenue and generating $12 million in free cash flow over the trailing twelve months.

The enterprise value is $394 million on $106 million of trailing revenue - roughly 3.7x sales - for a company with an 87% gross margin and a balance sheet that's net cash.

The risk

The bear case is straightforward. Zevra's GAAP operating margin is still negative at roughly -4.4% on a trailing basis, and the NPC market is small - it's a rare disease with a limited patient population. Long-term growth will depend on EU approval, VEDS trial success, or an acquisition. SG&A run rate of $20+ million per quarter is substantial relative to current revenue. If EU approval stalls or enrollment slows materially in the DiSCOVER trial, the pipeline optionality evaporates and the stock becomes a one-product play on a niche market.

A major economic downturn could also pressure the rare disease reimbursement environment, though orphan drugs have historically maintained coverage even in recessions.

The setup

The stock has declined roughly 28% over the past 20 trading sessions, down from its 52-week high of $15.04 to the $10 level. That pullback widened the gap between fundamentals and valuation rather than closing it. The Canaccord presentation gives CEO Neil McFarlane a platform to update investors on the EU timeline, VEDS enrollment pace, and the revenue trajectory ahead of Q2 earnings.

AInvest's aggregate signal labels the stock Buy, with a fundamental rating of 9.72 out of 10. Opaque scores aren't a thesis, but they do align with what the forward multiple and cash position show: the valuation doesn't match the growth rate.

Zevra appears to be a commercial-stage business priced like a speculation. The stock may need to stabilize around the $9-$10 zone before the setup becomes more attractive for patient capital, but the forward math is already compelling. At only 4x forward earnings on a company growing revenue at 200% with $237 million in cash and a path to EU approval, the disconnect is the opportunity.